Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study
Findings from this study support current literature, provide further insights into the characteristics and clinical management of irAEs and support an association between the development of an irAE and improved OS in these patient groups.
Authors
- Ricky Frazer (ORCID: https://orcid.org/0009-0002-0509-1506)
- David Farrugia (ORCID: https://orcid.org/0000-0001-9777-1394)
- Gabrielle Emanuel
- Simon D'Mello
- Judith Carser
- Anna Claire Olsson-Brown (ORCID: https://orcid.org/0000-0001-7721-5817)
- Ankit Jain (ORCID: https://orcid.org/0000-0002-5733-9705)
- John Houghton
- Ruth D. Lewis
Institutions
- Belfast Health and Social Care Trust (GB)
- Gloucestershire Hospitals NHS Foundation Trust (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Bristol-Myers Squibb (Italy) (IT)
- Velindre Cancer Centre (GB)
- The Royal Wolverhampton NHS Trust (GB)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-05-31
- DOI
- https://doi.org/10.1007/s40487-025-00349-z
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23